New York City’s life-sciences market showed signs of activity in 2025, with a strong fourth quarter boosting annual leasing totals despite a drop in asking rents and an increase in available move-in-ready lab space. Tenants leased approximately 377,000 square feet of lab and lab-ready space last year, with brokers noting that the increase was driven by a few large deals rather than widespread new demand. With major campus projects underway and new biotech IPOs bringing additional funding, landlords are monitoring whether the market’s recovery continues.
Numbers at a glance
According to CBRE, New York logged about 163,000 square feet of leasing in the fourth quarter and roughly 377,000 square feet for the full year, a 138 percent increase over the prior year. The same data put lab-exclusive availability near 27.4 percent and occupancy-ready, built lab availability at about 11.8 percent, while average asking rent for lab space slipped to $96.45 per square foot in the fourth quarter.
What brokers are saying
Despite the headline jump, local brokers describe a market that still feels slow. As reported by Crain's New York Business, CBRE Vice Chairman William Hartman said demand is "still pretty anemic" even as "the bleeding seems to have stopped," arguing that the recent pickup reflects a few sizable commitments rather than widespread tenant expansion.
Money returns, cautiously
A fresh run of biotech IPOs in early February has injected some capital and optimism into the sector, potentially giving companies more room to sign new leases or grow existing footprints. Coverage in BioPharma Dive and reporting that republishes Reuters coverage note that multiple drug developers, including Eikon Therapeutics, AgomAb and SpyGlass, all priced public offerings in the same week, raising hundreds of millions of dollars.
Pipeline still looms large
The city is also pushing ahead on large life-sciences projects that would pour substantial new lab capacity into the market, complicating the question of how quickly existing space can be absorbed. As per NYCEDC, proposals for Kips Bay and Innovation East envision millions of square feet of academic and research space. At the same time, industry observers including The Real Deal report that some developers are already calling for flexibility to avoid a potential glut.
What landlords and tenants should expect
On the ground, the market is tilting toward plug-and-play labs and beefed-up tenant-improvement packages as owners compete for a smaller pool of active tenants. Market trackers including CBRE show occupancy-ready availability on the rise, and analysis from Cushman & Wakefield points to shorter average lease terms and larger allowances becoming standard bargaining chips in the current environment.
Bottom line
New IPOs and renewed investment are contributing to activity in New York’s biotech sector, though brokers and developers note that the recovery remains uneven and concentrated among a limited group of well-funded tenants. For now, headline rents are under pressure, and landlords are focusing on filling turn-key lab suites as the market monitors whether early 2026 public-market gains lead to wider, sustained leasing.
.jpg){kind=link}